Explore ADB-FUBINACA | PiHKAL · info

Exploring ADB-FUBINACA. To explore a different substance…

Names

ADB-FUBINACA
ADMB-FUBINACA

IUPAC name

N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide

ID 4520 · Formula C₂₁H₂₃FN₄O₂ · Molecular weight 382.431

Tags Cannabinoid

InChI InChI=1S/C21H23FN4O2/c1-21(2,3)18(19(23)27)24-20(28)17-15-6-4-5-7-16(15)26(25-17)12-13-8-10-14(22)11-9-13/h4-11,18H,12H2,1-3H3,(H2,23,27)(H,24,28)/t18-/m1/s1

InChI Key ZSSGCSINPVBLQD-GOSISDBHSA-N This stereoisomer Any stereoisomer

SMILES NC(=O)[C@H](C(C)(C)C)NC(=O)c1nn(c2c1cccc2)Cc1ccc(cc1)F

ChemSpider 98645292
PubChem 58124399
Project Response ADB-FUBINACA (1793-17)
swgdrug.org ADB-FUBINACA
aipsin.com ADB-FUBINACA (Iss. 3, Jun-Sep 2019: VII-5)

Lee, JH; Park, HN; Leem, T; Jeon, J; Cho, S; Lee, J; Baek, SY. Identification of new synthetic cannabinoid analogue APINAC (adamantan-1-yl 1-pentyl-1H-indazole-3-carboxylate) with other synthetic cannabinoid MDMB(N)-Bz-F in illegal products. Forensic Toxicol., 1 Jan 2017, 35 (1), 45–55. 1.3 MB. https://doi.org/10.1007/s11419-016-0331-z

EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB.

EMCDDA. New drugs in Europe, 2013, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2014. 311 kB.

Smolianitski-Fabian, E; Cohen, E; Dronova, M; Voloshenko-Rossin, A; Lev, O. Discrimination between closely related synthetic cannabinoids by GC-Cold-EI-MS. Drug Test. Anal., 1 Mar 2018, 10 (3), 474-487. 1.3 MB. https://doi.org/10.1002/dta.2247

Hess, C; Murach, J; Krueger, L; Scharrenbroch, L; Unger, M; Madea, B; Sydow, K. Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples. Drug Test. Anal., 1 May 2017, 9 (5), 721-733. 267 kB. https://doi.org/10.1002/dta.2030 #ADB FUBINACA LC,MS

Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #8. ADB-FUBINACA

Noble, C; Cannaert, A; Linnet, K; Stove, CP. Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors. Drug Test. Anal., 2 Oct 2018, 11 (3), 501-511. 935 kB. https://doi.org/10.1002/dta.2517 #9

Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #61

Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #47

Kronstrand, R; Guerrieri, D; Vikingsson, S; Wohlfarth, A; Gréen, H. Fatal poisonings associated with new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 495–541. 477 kB. https://doi.org/10.1007/164_2018_110 #ADB-FUBINACA

Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298, 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #ADB-FUBINACA

Dimmito; Stefanucci; Pieretti; Minosi; Dvorácskó; Tömböly; Zengin; Mollica. Discovery of orexant and anorexant agents with indazole scaffold endowed with peripheral antiedema activity. Biomolecules, 16 Sep 2019, 9 (9), 492. 4.3 MB. https://doi.org/10.3390/biom9090492 #ADB-FUBINACA LC,MS,NMR

Kikura-Hanajiri, R. New designer drugs in japan. In Neuropathology of Drug Addictions and Substance Misuse; Preedy, VR, Ed., Academic Press, 1 Jan 2016; pp 1055–1065. 682 kB. https://doi.org/10.1016/B978-0-12-800212-4.00097-2 #ADB-FUBINACA

Åstrand, A; Guerrieri, D; Vikingsson, S; Kronstrand, R; Green, H. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT_1A, and 5-HT2_A receptors—On-target receptor potency and efficacy, and off-target effects. Forensic Sci. Int., 1 Dec 2020, 317, 110553. 1.7 MB. https://doi.org/10.1016/j.forsciint.2020.110553 #ADB-FUBINACA

Wouters, E; Mogler, L; Cannaert, A; Auwärter, V; Stove, C. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L‐valine or L‐ tert ‐leucine. Drug Test. Anal., 1 Aug 2019, 11 (8), 1183–1191. 1.4 MB. https://doi.org/10.1002/dta.2607 #20

APP-4F-BUT7AICA

APP-4F-BUTINACA

7 Dec 2019 · · Isomer Design